That’s right. To reach the $99.1M operating-profit threshold for reverting to the old profit-share scheme during the current launch year, NVS will need to sell about $150M of its generic Lovenox. Since NVS was averaging about $250M per quarter prior to the AG launch, $150M should be easy to do in quarter or so, even with the AG on the market.
*Assuming the appellate court does not overturn the PI.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.